Adult stem cells help patients with kidney disease

10-Jun-2015 - Mesoblast Limited announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and ...

Mesoblast’s Neofuse stem cell product shows positive results in Phase 2 lumbar fusion trial

Results support progression of clinical development to Phase 3

16-Jan-2013 - Mesoblast Limited announced that its Phase 2 clinical trial for lumbar spinal fusion had met its safety and efficacy endpoints. The results suggest that Mesoblast’s NeoFuse product comprising allogeneic Mesenchymal Precursor Cells (MPCs) is as effective for interbody lumbar fusion as the gold ...

Positive Outcome from FDA Meeting for Type 2 Diabetes Clinical Program Using Intravenous Delivery of Mesoblast's Proprietary Adult Stem Cells

24-Nov-2011 - Mesoblast Limited announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in ...

Mesoblast Reports Positive Results Using Intravenously Injected Adult Stem Cells for Type 2 Diabetes

15-Nov-2011 - Mesoblast Limited announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by ...

Licensing Executives Society (U.S.A. and Canada) 2011 Deals of Distinction Award for Life Sciences to Mesoblast, Cephalon Alliance

21-Oct-2011 - Mesoblast Limited and its strategic alliance partner Cephalon Inc. were awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction™ Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences ...

Mesoblast and Lonza establish strategic global manufacturing alliance

30-Sep-2011 - Mesoblast Limited and Lonza Group announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products.The alliance will provide Mesoblast with significant commercial advantages, including ...